Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Prognostic Factors in Prostate Cancer
share announcement

Prognostic Factors in Prostate Cancer

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 11666

Special Issue Editors

Prof. Dr. Michael H. Muders

E-Mail Website
Guest Editor
Rudolf-Becker-Laboratory, Institute of Pathology, University of Bonn Medical Center, Bonn, Germany
Interests: prostate cancer; pancreatic cancer; bladder cancer; neuropilin-2; bone metastasis; macrophage biology; autophagy; therapy resistance; prognostic and predictive markers in cancer
Dr. Angelika Borkowetz

E-Mail Website
Guest Editor
University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
Interests: prostate cancer; imaging; biomarkers; focal therapy
Prof. Benjamin Teply

E-Mail
Guest Editor
Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE USA 68132
Interests: prostate cancer; hormonal therapy; chemotherapy; biomarkers; therapeutic resistance; clinical trials

Special Issue Information

Dear Colleagues,

Gleason scoring and TNM staging are still the gold standards for the estimation of prostate cancer prognosis. In the meantime, molecular methods to predict the prognosis of lung, breast, and other cancers increasingly complement conventional diagnostic tools and are an important guide for therapy decisions and therapeutic target validation. For example, DNA methylation or transcript profiling as well as innovative proteomic analyses might represent instruments for future risk stratification and treatment decisions. This Special Issue of Cancers focuses on new prognostic or predictive markers in prostate cancer that have the potential to improve clinical decision making. 

Specifically, we are looking for manuscripts that:

  • Describe novel biomarkers in blood serum or liquid biopsies;
  • Study novel tissue based biomarkers or biomarker panels;
  • Allow for a better treatment stratification in early hormone naïve and late castration-resistant prostate cancer;
  • Uncover novel mechanistic insights in prostate cancer initiation, progression, and metastases.
Prof. Dr. Michael H. Muders
Dr. Angelika Borkowetz
Prof. Benjamin Teply
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acinar adenocarcinoma of the prostate
  • prostate cancer
  • prognostic markers
  • predictive markers
  • biomarkers
  • liquid biopsy
  • urology
  • oncology
  • pathology
  • therapy resistance
  • clinical trial

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 595 KiB  
Review
The Role of Perineural Invasion in Prostate Cancer and Its Prognostic Significance
by Yuequn Niu, Sarah Förster and Michael Muders
Cancers 2022, 14(17), 4065; https://doi.org/10.3390/cancers14174065 - 23 Aug 2022
Cited by 12 | Viewed by 5289
Abstract
Perineural invasion (PNI) is a common indication of tumor metastasis that can be detected in multiple malignancies, including prostate cancer. In the development of PNI, tumor cells closely interact with the nerve components in the tumor microenvironment and create the perineural niche, which [...] Read more.
Perineural invasion (PNI) is a common indication of tumor metastasis that can be detected in multiple malignancies, including prostate cancer. In the development of PNI, tumor cells closely interact with the nerve components in the tumor microenvironment and create the perineural niche, which provides a supportive surrounding for their survival and invasion and benefits the nerve cells. Various transcription factors, cytokines, chemokines, and their related signaling pathways have been reported to be important in the progress of PNI. Nevertheless, the current understanding of the molecular mechanism of PNI is still very limited. Clinically, PNI is commonly associated with adverse clinicopathological parameters and poor outcomes for prostate cancer patients. However, whether PNI could act as an independent prognostic predictor remains controversial among studies due to inconsistent research aim and endpoint, sample type, statistical methods, and, most importantly, the definition and inclusion criteria. In this review, we provide a summary and comparison of the prognostic significance of PNI in prostate cancer based on existing literature and propose that a more standardized description of PNI would be helpful for a better understanding of its clinical relevance. Full article
(This article belongs to the Special Issue Prognostic Factors in Prostate Cancer)
►▼ Show Figures

Figure 1

28 pages, 2427 KiB  
Review
Comparative Pathobiology of Canine and Human Prostate Cancer: State of the Art and Future Directions
by Eduardo de Paula Nascente, Renée Laufer Amorim, Carlos Eduardo Fonseca-Alves and Veridiana Maria Brianezi Dignani de Moura
Cancers 2022, 14(11), 2727; https://doi.org/10.3390/cancers14112727 - 31 May 2022
Cited by 4 | Viewed by 2773
Abstract
First described in 1817, prostate cancer is considered a complex neoplastic entity, and one of the main causes of death in men in the western world. In dogs, prostatic carcinoma (PC) exhibits undifferentiated morphology with different phenotypes, is hormonally independent of aggressive character, [...] Read more.
First described in 1817, prostate cancer is considered a complex neoplastic entity, and one of the main causes of death in men in the western world. In dogs, prostatic carcinoma (PC) exhibits undifferentiated morphology with different phenotypes, is hormonally independent of aggressive character, and has high rates of metastasis to different organs. Although in humans, the risk factors for tumor development are known, in dogs, this scenario is still unclear, especially regarding castration. Therefore, with the advent of molecular biology, studies were and are carried out with the aim of identifying the main molecular mechanisms and signaling pathways involved in the carcinogenesis and progression of canine PC, aiming to identify potential biomarkers for diagnosis, prognosis, and targeted treatment. However, there are extensive gaps to be filled, especially when considering the dog as experimental model for the study of this neoplasm in humans. Thus, due to the complexity of the subject, the objective of this review is to present the main pathobiological aspects of canine PC from a comparative point of view to the same neoplasm in the human species, addressing the historical context and current understanding in the scientific field. Full article
(This article belongs to the Special Issue Prognostic Factors in Prostate Cancer)
►▼ Show Figures

Figure 1

19 pages, 358 KiB  
Review
Biomarkers for Treatment Response in Advanced Prostate Cancer
by Samia Asif and Benjamin A. Teply
Cancers 2021, 13(22), 5723; https://doi.org/10.3390/cancers13225723 - 16 Nov 2021
Cited by 14 | Viewed by 2794
Abstract
Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies—specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients need to [...] Read more.
Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies—specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients need to be treated with the therapies that are most likely to provide benefit and avoid toxic therapies that are unlikely to be effective. Ideally, predictive biomarkers that allow for the selection of the therapies most likely to be of benefit would be employed for each treatment decision. In practice, biomarkers including tumor molecular sequencing, circulating tumor DNA, circulating tumor cell enumeration and androgen receptor characteristics, and tumor cell surface expression (PSMA), all may have a role in therapy selection. In this review, we define the established prognostic and predictive biomarkers for therapy in advanced prostate cancer and explore emerging biomarkers. Full article
(This article belongs to the Special Issue Prognostic Factors in Prostate Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop